13/12/2022

EuropaBio Principles for Genetic Testing and Testing for Genetically-Driven Risk Factor

European Industry trade and supply chain needs to respond to Covid-19 - Joint Letter to the EU Trade Ministers.
28/11/2022

Enabling Patient Access to Transformational Therapeutic Innovations: Modernising the EU’s Cross-Border Healthcare Framework

European Industry trade and supply chain needs to respond to Covid-19 - Joint Letter to the EU Trade Ministers.
11/11/2022

The Revision of the Orphan Medicines Regulation Is an Opportunity. Will Europe Seize it?

20/10/2022

Ensuring the full potential of EHDS: Stakeholders’ recommendations on how to make the digital transformation a success across Europe

19/10/2022

#EFIB2022:  Industrial biotechnology community comes together in Vilnius next week

06/10/2022

EuropaBio celebrates its inaugural Healthcare BioForum

31/01/2022

EuropaBio becomes a partner of a new European partnership for health

26/10/2021

Healthy Planet, Healthy People: a Pathway for Green Transition in the Biopharmaceutical Ecosystem

29/06/2021

A Declaration from Members of the World’s Biotechnology Sector On Global Access to COVID Vaccines & Treatments and the Role of Intellectual Property

We, the undersigned CEOs of global biotechnology companies and associations have a social responsibility to work with other stakeholders to ensure that COVID vaccines and treatments get to the patients in the world who most need them.
07/06/2021

Pragmatic IP solutions and strong collaborations will ensure faster global access to vaccines

31/05/2021

EuropaBio Key Messages to 94th Pharmaceutical Committee – 28 May 2021

27/05/2021

EuropaBio meets EMA to exchange views on topics of common interest

2021_05_H_O_EMA-EuropaBio bilateral meeting_Agenda items 1 & 2 2021_05_H_O_EMA-EuropaBio bilateral meeting_Agenda items 4 & 5
07/05/2021

IP waiver for COVID-19 vaccines is a misguided and ineffective response to a shared global challenge

2021_05_H_PR_Waiver of Intellectual Property Rights for COVID-19 Vaccines – EuropaBio’s Position
03/05/2021

EuropaBio launches a new Biopharmaceutical Strategy Group

16/04/2021

Online Roundtable Report: An EU Vision For Life Science and Biotechnology for a Healthy and Sustainable EU

Webinar Report.
25/03/2021

EuropaBio Statement – Vaccine production scale up: International collaboration remains the key

EuropaBio Statement – Vaccine production scale up: International collaboration remains the key.
22/03/2021

EuropaBio and P-BIO launch the National Associations Council Summit 2021 – Building on Biotechnology: from vaccines to Economic Growth for Europe

EuropaBio and P-BIO launch the National Associations Council Summit 2021 - Building on Biotechnology: from vaccines to Economic Growth for Europe
29/01/2021

Building a European Health Union

EuropaBio welcomes the European Health Union plan. The EU has indeed a critical role to play in public health and better crisis preparedness to address serious cross-border health threats and improving crisis management capacity.
28/01/2021

European Biotech Associations Letter to the European Commission regarding the ongoing evaluation of the Orphan Medicinal Products Regulation

Read the European Biotech Associations Letter to the European Commission regarding the ongoing evaluation of the Orphan Medicinal Products Regulation.
20/01/2021

Revision of the EU legislation on medicines for children and rare diseases

Read our submission to the European Commission’s Inception Impact Assessment titled “Revision of the EU legislation on medicines for children and rare diseases“.